Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer

Claudin 18.2 (CLDN18.2) is a tight-junction protein. CLDN18.2-targeting strategy has cut a striking figure in CLDN18.2 positive patients with advanced gastric cancer. Zolbetuximab, the CLDN18.2 antibody, obtained a better clinical benefit in patients compared with the controlled. In phase II trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianwei, Dong, Ruilan, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219097/
https://www.ncbi.nlm.nih.gov/pubmed/32410803
http://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219097/
https://www.ncbi.nlm.nih.gov/pubmed/32410803
http://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.13

Ejemplares similares